Table 1

Effects of GnRH-a treatment on clinical features, height standard deviation (SD) for chronological age, and height SD for bone age in GDPP due to hypothalamic hamartoma

PatientCA at onset of GnRH-a treatment (years)Age at treatment (years)BaselineLatest visit
Tanner stageHeight SD
for CA
Height SD
for BA
Tanner StageHeight SD
for CA
Height SD
for BA
11.338.4G2PH1+0.21+1.46G1PH1−0.47+1.37
21.913.4G2PH3+2.90−1.32G1PH2+2.24+0.60
32.162.8G2PH1+0.20+0.20G1PH1+1.09+0.68
41.163.6G2PH2+2.81+0.16G1PH1+3.05+1.59
51-150 2.55.0G4PH4+5.87−0.51
61.336.9B3PH1+1.04−0.66B3PH1+3.11+0.02
71.834.1B4PH3+3.0−3.71B3PH3+3.52+0.46
81.082.7B2PH1+1.04−2.60B1PH1+0.33+3.10
Mean (SD)1.66 (0.51)4.61 (2.05)+1.60 (1.27)−0.92 (1.77)+1.83 (1.54)+1.11 (1.02)
Range1.08 to 2.52.66 to 8.410.2 to 3.0−3.71 to 1.46−0.47 to 3.520.02 to 3.10
  • 1-150 Case 5 was not included in the statistical analysis; p < 0.05 (baseline height SD for bone age v latest height SD for bone age).

  • CA, chronological age; BA, bone age; B, breast; PH, pubic hair; G, genitalia (testicular size), according to Tanner’s criteria.